Recent performance snapshot and business scale

UnitedHealth Group (UNH) has seen its stock gain 3.1% over the past month and 28.9% over the past 3 months, with a 29.5% total return over the past year.

The company reports annual revenue of US$449.7b and net income of US$12.0b, supported by multiple segments that include UnitedHealthcare insurance operations and the Optum health services businesses.

Short term momentum has cooled slightly, with the share price down 2.1% over the past week after a strong 28.9% share price return over the last three months. The 3 year total shareholder return shows a decline, which keeps longer term performance in focus as investors weigh how recent moves fit with UnitedHealth Group's current valuation and business scale.

If you are comparing UnitedHealth Group with other opportunities in the sector, this is a good time to scan for US healthcare stocks using AI in their services with the 39 healthcare AI stocks

With UnitedHealth Group trading around US$380.31 and an internal intrinsic value estimate suggesting a sizable discount, investors are left with a key question: is this genuine value on offer, or is the market already pricing in future growth?

Most Popular Narrative: 21.9% Undervalued

At a last close of $380.31 against a narrative fair value of $486.86, the widely followed view argues that UnitedHealth Group trades at a meaningful discount.

UNH benefits from several industry tailwinds:

Expanding Premium Base: UNH’s premium base continues to grow, contributing to its revenue growth.

Contract Wins: The company secures contracts and renewals, such as the recent contract win in Michigan to serve Medicaid beneficiaries.

Strength in Optum Business: Optum, a subsidiary of UNH, contributes significantly to its overall performance.

Solid Financial Position: UNH’s financial stability reinforces investor confidence.

Aging Population: The aging U.S. population sustains demand for UNH’s Medicare plans.

Impressive Earnings Surprise History: UNH consistently outperforms earnings estimates.

Robust Growth Prospects: The consensus estimates for 2024 and 2025 indicate growth in both earnings and revenues.

Strong Return on Equity: UNH efficiently utilizes shareholders’ funds with a higher return on equity than the industry average.

Want to see what sits behind that valuation gap? The narrative leans heavily on continued premium expansion, Optum’s contribution, and long term margin assumptions that are anything but timid.

Result: Fair Value of $486.86 (UNDERVALUED)

However, this hinges on continued regulatory support and successful tech execution, with changes to Medicare or missteps in digital investments both capable of closing that valuation gap.

Another View: What P/E Is Telling You

The user narrative leans on a fair value of $486.86, yet the current P/E of 28.7x is higher than the US Healthcare industry at 23.2x, even though it sits below peers at 32.2x and an estimated fair ratio of 39.9x. That mix of premium and headroom leaves an open question: is the risk skewed toward multiple compression or further rerating?

To see how this P/E picture fits with the rest of the valuation work, including earnings quality and growth assumptions, take a closer look at the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Sentiment here is mixed, with both upside arguments and clear watchpoints. Act while the data is fresh and weigh the company on its own terms using the 3 key rewards and 2 important warning signs

Looking for more investment ideas?

Do not stop your research with a single stock. Broaden your watchlist now or risk missing opportunities that could better match your goals and risk comfort.

• Hunt for quality at a discount by scanning 46 high quality undervalued stocks that pair solid fundamentals with prices that may not fully reflect their strengths.
• Strengthen your income stream by zeroing in on 10 dividend fortresses that focus on higher yields alongside resilience.
• Stay on the front foot with 63 resilient stocks with low risk scores designed to spotlight companies with more resilient risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.